POLYCYSTIC
OVARY SYNDROME (PCOS) AND LOW CARBOHYDRATE DIET
Polycystic ovary syndrome (PCOS) is a complex, multi-faceted
syndrome characterized clinically by high levels of androgen
hormones (such as testosterone), high levels of insulin, lower
abdominal obesity, acne, masculine hair growth patterns, and
menstrual irregularities. A review of some of the scientific
literature regarding PCOS suggests that one effective strategy
for ameliorating the symptoms of PCOS may indeed be a low carbohydrate
diet that tightly controls blood glucose and insulin levels.
While the underlying reason is still not entirely clear, research
shows that women with PCOS develop very significant insulin resistance,
meaning that their tissues become less sensitive to the message
insulin sends to them to take glucose from the blood and move
it into tissues to be used for energy. There is recent evidence
suggesting that, in fact, women with PCOS may have a defect in
the normal pattern of cell signaling that takes place when insulin
binds to the receptors of cells. In any case, a scenario of reduced
insulin sensitivity is also characteristic of type II diabetes
mellitus, and indeed there is research suggesting that women
with PCOS are at a significantly increased risk of developing
type II diabetes. High levels of insulin resistance in patients
with PCO are also associated with low levels of HDL-cholesterol,
the 'good cholesterol', and might help explain part of the increased
risk patients with PCO have of cardiovascular disease. Other
contributing factors to this increased risk of cardiovascular
disease in patients with PCO may be chronic inflammation, as
evidenced by increased levels of the inflammatory marker C-reactive
protein, and increased levels of oxidative stress.
Another important aspect of high blood insulin levels is the
relationship between high insulin and the lowered levels of sex
hormone binding globulin (SHBG) it may cause. SHBG is the protein
made by the body to help remove estrogens and testosterone from
the circulation, limiting the effects of these powerful hormones.
Both high blood glucose levels and high blood insulin levels
are associated with decreased levels of SHBG, and both insulin
and insulin-like growth factor have been shown to down regulate
the liver cells' production of SHBG. In one study of women with
and without PCOS placed on a low calorie diet, both groups of
women showed more than doubled amounts of SHBG, decreased insulin,
and also importantly for women with PCOS, a decrease in testosterone.
A similar protocol, when carried out for 6-7 months also resulted
in more normalized menstrual cycles and increased fertility.
There is a lot to learn from research done in the area of glucose
control with patients of PCOS, and though some studies emphasize
pharmaceutical prescriptions over the effects of a low carbohydrate
diet, they do illustrate how effective glucose control can be
in the treatment of patients with PCOS. For example, a recent
study has shown that women with PCOS who are treated with metformin,
a drug used to decrease liver glucose production and possibly
increase insulin receptor sensitivity, saw somewhat decreased
levels of androgen production. When this approach was combined
with a high protein-low carbohydrate diet in teenage women with
PCOS, 10 of 11 subjects resumed a normal menstrual cycle, on
average after 10.5 months of treatment. In addition, other markers
of PCOS were improved, with increased estrogen and progesterone,
a trend toward decreased testosterone, and decreased total cholesterol.
In another study acarbose, a medication that slows the release
of glucose from the gastrointestinal tract to the body, was given
to patients with PCOS. After three months of treatment the patients
with PCOS showed a significant reduction of hirsutism (male patterns
of hair growth) and acne. The patients also experienced a lower
release of insulin in response to a glucose challenge, a reduction
in the levels of the androgen hormones testosterone and androstenedione,
an increase in SHBG, and 8 of the 30 patients with PCOS began
to have regular menstrual cycles.
While pharmaceutical approaches, alone or combined with a low
carbohydrate diet are certainly helpful, it is also important
to emphasize the benefit that may be obtained exclusively by
following a diet low in refined carbohydrate. This is ultimately
the strategy that is the least expensive and teaches the patient
that they have the ability, to a large extent, to maintain their
health by choices made in daily living. In this light, the results
of an Italian study, the DIANA study, are especially interesting.
While this study did not use a study group of women diagnosed
with PCOS (though some of the women in the study may also have
been women with PCOS), the study's subjects were 104 women with
the highest levels of testosterone out of 312 women screened.
Thus, like women diagnosed with PCOS, these subjects tended to
high androgen levels. The treatment group of the study received
a highly controlled diet rich in whole grain cereals, seeds (such
as flax), berries, cruciferous vegetables, and other vegetables.
They also increased their amounts of fish, seaweed, and olive-oil
intake, while consuming greater quantities of legumes and soy
products. Meat, eggs, and dairy were only consumed once a week
and refined carbohydrates, such as white bread, processed white
flour and sucrose were discouraged. After eighteen weeks, the
subjects with this modified diet showed a 25% increase in SHBG,
a 19.5% decrease in testosterone, and a significant decrease
in the amount of insulin released in response to a glucose challenge,
compared to controls. The diet in the intervention group also
accounted for a loss of about 7.7lbs, which may have actually
been the most important factor in the reduction of testosterone.
In short, given the prevalence of high insulin levels in women
with PCOS and the reduction in androgen levels that accompany
glucose and insulin control, it is very reasonable to focus on
controlling glucose and insulin as a clinical strategy in treating
women with PCOS. While some pharmaceutical interventions, such
as metformin and acarbose are helpful in this regard, the basis
of the approach is best based upon sound dietary choices that
substantially restrict refined carbohydrates, include high quality
protein, and provide omega-three and monounsaturated fatty acids.
1.Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral
insulin resistance, independent of obesity, in polycycstic ovary
syndrome.Diabetes 1989; 38(9):1165-74.
2.Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin
receptor signaling in vivo in the polycystic ovary syndrome (PCOS).
Am J Physiol Endocrinol Metab 2001; 281(2):E392-9.
3. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative
risk of conversion from normoglycaemia to impaired glucose tolerance
or non-insulin dependent diabetes mellitus in polycystic ovarian
syndrome. Human Reprod 2001; 16(9):1995-8.
4. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan
R, Bush A, Richmond W, Johnston DG, Franks S. Dyslipidaemia is
associated with insulin resistance in women with polycystic ovaries.
Clin Endocrinol (Oxf) 1996; 44(3):277-84.
5. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar
N. Low grade chronic inflammation in women with polycystic ovarian
syndrome. J Clin Endocrinol Metab 2001; 86(6):2453-5.
6. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in
polycystic ovary syndrome and its contribution to the risk of
cardiovascular disease. Clin Biochem 2001; 34(5):407-13.
7. Botwood N, Hamilton-Fairley D, Kiddy D, Robinson S, Franks
S. Sex hormone-binding globulin and female reproductive function.
J Steroid Biochem Mol Biol 1995; 53(1-6):529-31.
8. Crave JC, Lejeune H, Brebant C, Baret C, Pugest M. Differential
effects of insulin and insulin-like growth factor I on the production
of plasma steroid-binding globulins by human hepatoblastoma-derived
(Hep G2) cells. J Clin Endocrinol Metab 1995; 80(4):1283-9.
9. Kiddy DS, Hamilton-Fairley D, Seppala M, Koistinen R, James
VH, Reed MJ, Franks S. Diet-induced changes in sex hormone binding
globulin and free testosterone in women with normal or polycystic
ovaries: correlation with serum insulin and insulin-like growth
factor-I. Clin Endocrinol (OXF) 1989;31(6):757-63.
10. Franks S, Kiddy DS, Hamilton-Fairley D, Bush A, Sharp PS,
Reed MJ. The role of nutrition and insulin in the regulation
of sex hormone binding globulin. J Steroid Biochem Mol Biol 1991;
39(5B):835-8.
11. Koivunen RM, Morin-Papunen LC, Ruokenen A, Tapanainen JS,
Martikainen HK. Ovarian steroidogenic response to human chorionic
gonadotrophin in obese women with polycystic ovary syndrome:
effect of metformin. Hum Repdrod 2001; 16(12):2546-51.
12. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin
to restore normal menses in oligo-amenorrheic teenage girls with
polycystic ovary syndrome (PCOS). J Adolesc Health 2001; 29(3):160-9.
13. Ciotta L, Calogero AE, Farina M, De Leo V, La Marca A, Cianci
A. Clinical, endocrine and metabolic effects of acarbose, an
alpha-glucosidase inhibitor, in PCOS patients with increased
insulin response and normal glucose tolerance. Hum Reprod 2001;
16(10):2066-72.
14. Berrino F, Bellati C, Secreto G, Camerini E, Pala V. Panico
S, Allegro G, Kaaks R. Reducing bioavailable sex hormones through
a comprehensive change in diet : the Diet and Androgens (DIANA)
Randomized Trial. Cancer Epidemiology Biomarkers and Prevention
2001; 10(1):25-33.